Meeting
2022 ASCO Annual Meeting
A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
Authors
Jianyong Li
Jiangsu Province Hospital, Nanjing, China
Jianyong Li , Keshu Zhou , Weiqi Nian , Guohui Cui , Jishi Wang , Xiaoping Zhang , Hong Cen , Fei Li , Shuhua Yi , Ru Feng , Chongyuan Xu , Wenbin Qian , Lihong Liu , Caixia Li , Xielan Zhao , Zi Chen , Junxiao Qiao , Hongli Zhang , Mohammad Ahmad , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT04494503
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7543)
DOI
10.1200/JCO.2022.40.16_suppl.7543
Abstract #
7543
Poster Bd #
196
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
First Author: Masa Lasica
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2016 ASCO Annual Meeting
Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL).
First Author: Matthew Steven Davids
Poster
2015 ASCO Annual Meeting
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Shaji Kumar